Peregrine Ventures
Peregrine Ventures is an Israeli healthcare-focused venture capital firm operating pre-seed, early/mid-stage, and late-stage funds, having built 60 companies with $5B aggregate portfolio value and strategic backing from major global pharma and medtech corporates.
- Company typePrivate
- Founded2001
- HeadquartersOr Yehuda, Israel
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Peregrine Ventures does
Peregrine Ventures is an Israeli venture capital firm founded in 2001 that operates as Israel's first dedicated healthcare investment platform. The firm manages three complementary vehicles spanning the company lifecycle: the Peregrine Incentive Incubator for pre-seed company formation, the Peregrine Ventures Fund for early- and mid-stage rounds, and the Peregrine Growth Fund for late-stage rounds. Across these vehicles, Peregrine has established 60 companies through its incubator program, of which 34 remain active, with an aggregate portfolio value of approximately $5B.
The firm's investment focus is healthcare and life sciences, including medical devices, biopharma, and digital health, anchored by strategic limited partner relationships with multinational pharmaceutical and medtech companies including Bristol-Myers Squibb, BD, Merck, Pfizer, AstraZeneca, and IBM, alongside Elbit Systems on the defense-biotech intersection. Peregrine benefits from a long-dated co-investment partnership with the Israel Innovation Authority, which matches up to 85% of early-stage investment over an eight-year horizon, materially de-risking seed-stage deployment.
The business model follows standard VC economics: management fees on committed and invested capital across the three funds, supplemented by carried interest on exits. Recent realized liquidity events include the sale of CartiHeal to Smith & Nephew (~$330M), BioProtect to Olympus (~$270M), CardioValve to Venus Medtech, and EndoStream to Kaneka. The firm maintains a small, partner-led operating team and has extended its geographic footprint beyond Israel into the United States, United Kingdom, and Singapore to source cross-border deals and follow-on capital.
Peregrine Ventures firmographics
Firmographics- Name
- Peregrine Ventures
- Legal name
- Peregrine Ventures Management Ltd.
- Website
- https://peregrinevc.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Peregrine Ventures is an Israeli healthcare-focused venture capital firm operating pre-seed, early/mid-stage, and late-stage funds, having built 60 companies with $5B aggregate portfolio value and strategic backing from major global pharma and medtech corporates.
- Ownership category
- akta.pro rank
Peregrine Ventures industry classification
Industry- Product category
- Healthcare Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
- akta.pro secondary industries
- Early-Stage Venture Capital (Series A/B) (FSANAAAB), Healthcare Access & Life Sciences Impact Funds (FSANAJAI)
Keywords
Where Peregrine Ventures is headquartered
LocationHeadquarters
- HQ city
- Or Yehuda
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
Peregrine Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Fund Management Fees: VC firms typically generate revenue through management fees charged on committed capital under management, typically ranging from 1.5-2.5% annually.
- Carried Interest/Investment Returns: Returns generated through successful exits of portfolio companies, including M&A transactions (CartiHeal acquired for $330M by Smith & Nephew, BioProtect acquired for $270M by Olympus, EndoStream acquired by Kaneka, CardioValve acquired by Venus Medtech) and IPOs (Neovasc, Eledon).
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Peregrine Ventures product offering
Product offeringCore offering
Peregrine Ventures is Israel's first dedicated healthcare venture capital fund, providing cross-stage equity investment and hands-on operational support to life sciences companies through three dedicated vehicles: the Incentive Incubator (pre-seed), the Peregrine Fund (early and mid-stage), and the Peregrine Growth Fund (late-stage pre-M&A/IPO). The firm invests across medical devices, pharma/biotech, and digital health, and provides portfolio companies with business development, regulatory navigation, team recruitment, and strategic alliance support.
Product overview
Peregrine Ventures is a venture capital firm offering three distinct investment vehicles for life science companies at different growth stages. The Incentive Incubator supports pre-seed companies with infrastructure, business development, and strategic planning; the Peregrine Fund targets early and mid-stage companies through development and regulatory phases; and the Peregrine Growth Fund assists mature companies in their final financing rounds before M&A or IPO. The firm does not offer a unified software product or platform—its offerings are financial investment vehicles, not technology products.
Differentiator
Problem solved
Functional benefit
Products and services
- Incentive Incubator Peregrine's technology incubator for pre-seed life sciences companies, providing technological infrastructure, financial management, business development support, strategic planning, and team recruitment assistance. Partners with pharma multinationals and research institutions. Has produced 60 companies with $5 billion aggregate value.
- Peregrine Fund (Early & Mid Stage) Investment vehicle providing capital and operational support to early and mid-stage life science companies, working closely with entrepreneurs during R&D, regulatory, reimbursement, and business operations phases.
- Peregrine Growth Fund Fund dedicated to mature companies in their final financing rounds prior to M&A or IPO, leveraging deep industry connections to facilitate successful exits at low risk with short time frames.
Quantifiable outcome
- The aggregate value of companies that have graduated from Incentive Incubator has reached $5 billion
- +4 more outcomes
Companies that use Peregrine Ventures
Customer profileSegments3 records
Ideal customer profiles4 records
Peregrine Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Peregrine Ventures partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, strategic, major and supporting.
- Bristol-Myers Squibb (BMS)corePharmaceutical multinational participating as a strategic investor in Peregrine's Incentive Incubator, supporting early-stage medical technology development alongside other major partners.
- Becton Dickinson and Company (BD)coreMedical devices company serving as a strategic investor in the Incentive Incubator consortium, contributing to the development of early-stage medical device companies.
- Elbit SystemscoreIsraeli defense contractor participating as a strategic investor in the Incentive Incubator, bringing defense technology expertise to medical technology development.
- MerckcoreGlobal pharmaceutical company joined as strategic partner in the Incentive incubator, enhancing pharmaceutical and biotech investment capabilities. Also conducting mutual clinical trials with portfolio company Nectin Therapeutics.
- Tel Aviv UniversitycoreResearch institute partner in the Incentive Incubator, contributing academic research capabilities to early-stage company development.
- Ben-Gurion University of the NegevcoreResearch institute partner providing scientific expertise and research capabilities to the Incentive Incubator ecosystem.
- Shaare Zedek Medical CentercoreMedical center partner contributing clinical research expertise to the Incentive Incubator alongside other prestigious research institutions.
- Israel Innovation AuthoritycoreGovernment authority that will match up to 85% of each early-stage investment by Incentive over eight years, significantly de-risking early-stage investments.
- IBMstrategicEntered into licensing agreement with portfolio company Variantyx, providing AI technologies for somatic analysis to develop comprehensive tumor diagnostic solutions.
- AstraZenecamajorLaunched pilot program with Cordio Medical's HearO app at Bellvitge University Hospital, testing voice analysis technology for heart failure monitoring.
- Biomed IsraelsupportingEyal Lifschitz of Peregrine Ventures co-hosts a panel at Biomed Israel's 24th annual forum, discussing convergence of medical devices, pharma, and software in healthcare.
- Immunome, Inc.strategicPortfolio company Nectin Therapeutics entered global license agreement granting Immunome exclusive rights to a panel of antibodies targeting an undisclosed pioneering target.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Peregrine Ventures competitors and assessment
Company assessmentDirect peers
- aMoon Fund: Israeli healthcare and life sciences venture capital firm investing across stages. Most direct competitor to Peregrine in the Israeli healthtech VC landscape with overlapping medical devices and digital health focus.
- Pontifax Venture Capital: Israeli healthcare-dedicated venture capital firm investing in life sciences and biotech. Directly comparable to Peregrine's stage-agnostic Israeli healthcare investment thesis.
- Arkin Holdings: Israeli healthcare-focused investment firm with venture, growth, and pharma services arms. Operates cross-stage healthcare investments out of Israel similar to Peregrine.
- Triventures: Israeli medical device and digital health venture capital firm. Comparable to Peregrine's early-stage Israeli healthtech investment focus with global strategic LP partnerships.
- Accelmed Partners: Israeli healthcare-dedicated private equity and venture capital firm investing in medical devices and life sciences. Overlapping portfolio focus with Peregrine in Israeli medical technology.
- Pitango HealthTech: Israeli venture capital firm with dedicated healthtech practice. Co-led the Restore Medical Series B with Peregrine and is a direct competitor in Israeli healthcare venture investing.
Broad incumbents
- OrbiMed Advisors: Global healthcare-dedicated investment firm across venture, growth, and public equities. Broader scale and geographic reach than Peregrine but operates in the same healthcare VC category.
- Atlas Venture: US-based early-stage life sciences venture capital firm. Comparable to Peregrine's early/mid-stage life sciences fund strategy with similar incubator-to-growth model.
- Longitude Capital: US healthcare-dedicated growth equity and venture capital firm. Comparable to Peregrine Growth Fund's late-stage healthcare investment thesis with similar medical device focus.
Regional players
- JVP (Jerusalem Venture Partners): Israeli venture capital firm with healthcare and life sciences portfolio exposure. Geographic peer with overlapping Israeli life sciences deal flow.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Peregrine Ventures social profiles
Digital presencePeregrine Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Peregrine Ventures leadership team
Management profileNumber of profiles
Profiles10 records
Peregrine Ventures subsidiaries and ownership
Company hierarchySubsidiaries3 records
Peregrine Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Peregrine Ventures M&A and investment
M&A and investmentM&A
Investments232 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Peregrine Ventures
What does Peregrine Ventures do?
Peregrine Ventures is Israel's first dedicated healthcare venture capital fund, providing cross-stage equity investment and hands-on operational support to life sciences companies through three dedicated vehicles: the Incentive Incubator (pre-seed), the Peregrine Fund (early and mid-stage), and the Peregrine Growth Fund (late-stage pre-M&A/IPO). The firm invests across medical devices, pharma/biotech, and digital health, and provides portfolio companies with business development, regulatory navigation, team recruitment, and strategic alliance support.
Is Peregrine Ventures a public or private company?
Peregrine Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Peregrine Ventures founded?
Peregrine Ventures was founded in 2001. It employs 1 to 10 people.
Where is Peregrine Ventures based?
Peregrine Ventures is headquartered in Or Yehuda, Israel, in the Middle East region.
How does Peregrine Ventures make money?
Two revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest/Investment Returns.
Who are Peregrine Ventures's main competitors?
Direct peers on record are aMoon Fund, Pontifax Venture Capital, Arkin Holdings, Triventures, Accelmed Partners and Pitango HealthTech. Broad incumbents are OrbiMed Advisors, Atlas Venture and Longitude Capital. JVP (Jerusalem Venture Partners) is listed as a regional player.
Does Peregrine Ventures have an API?
No public API is recorded for Peregrine Ventures.
What industry is Peregrine Ventures in?
Peregrine Ventures's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 523940 and its SIC code is 6282.